Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Tonix Pharmaceuticals Holding Corp

TNXP ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Micro Cap Analyst: BUY

Last Close

$13.66

▲ +9.72%

Market Cap $234.28M · Vol 272.32K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$234.28M

Micro Cap

Div Yield

N/A

EPS Growth

+29.75%

YoY

RSI (14)

75.97

Momentum

Beta

1.73

vs Market

52W High

$34.50

60.41% below

52W Low

$9.43

44.86% above

Volume

272.32K

Avg 128.51K

P/B

0.81

Price-to-book

ROE

N/A

Return on equity

Free Float

99.81%

Public shares

Shariah Compliance8 STANDARDS

✗ Tonix Pharmaceuticals Holding Corp (TNXP) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does TNXP pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+7.90%

+38.26%

+6.97%

-7.95%

YTD

-12.55%

-60.51%

-99.54%

-100.00%

Financials & Valuation

TTM · Annual

Total Revenue	$13.11M
Net Income	$-124,021,000.00
Revenue Growth (YoY)	+577.88%
Gross Margin	49.34%
Operating Margin	-959.05%
Net Profit Margin	-946.22%
ROE	N/A
ROA · ROIC	-56.37% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	10.14
P/B	0.81
P/FCF	N/A
EPS Growth	+29.75%
Outstanding Shares	17.15M

Technical Indicators

50-Day SMA	$11.86
200-Day SMA	$14.24
RSI (14)	75.97
Beta	1.73
52-Week High	$34.50
52-Week Low	$9.43

Volume Today	272.32K
Avg Daily Volume (30D)	128.51K
Relative Volume	2.12x
Volatility (10D)	53.99
Volatility (30D)	75.30
Free Float	99.81%

Analyst Consensus

BUY

Current Price $13.66

Mean Target $42.40

52W Low$9.43 52W High$34.50

Current

Target

$9.43 $34.50

Current Analyst target

+210.40% upside potential · 5 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001T49NZ9

ISINUS8902608392

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -1.06% JNJ Johnson & Johnson +0.04% ABBV Abbvie Inc +0.48% NVS Novartis AG +1.24% NOVN.S Novartis AG +1.25%

Company Profile

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.